Last reviewed · How we verify
NCT03254186
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
Phase 2, PHASE3 trial testing Propranolol Hydrochloride in Tardive Dyskinesia. Withdrawn.
1 February 2019
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Start date | 18 September 2017 |
| Primary completion | 1 February 2019 |
| Estimated completion | 1 February 2019 |
Drugs / interventions tested
- Propranolol Hydrochloride — full drug profile →
- Placebo Oral Tablet — full drug profile →
Conditions studied
- Tardive Dyskinesia — all drugs for Tardive Dyskinesia →
Sponsor
Emory University
Who can join
Adults 18 to 75, any sex, with Tardive Dyskinesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tardive dyskinesia (TD) is a disabling, embarrassing and often irreversible iatrogenic movement disorder that can occur in anyone exposed to drugs that block dopamine receptors, including first and second generation antipsychotics and antiemetic agents. There is no way to prevent TD except preventing exposure to the inciting agents and there are no approved symptomatic therapies. Propranolol is an FDA-approved β-blocker with limited data supporting its use as a treatment for TD. The goal of this study is to determine the efficacy of propranolol in the treatment of TD in a double-blind, cross-over prospective manner. If propranolol is found to be an effective therapy, it will fulfill a great need in the treatment of TD with a medication that is known to be safe and inexpensive.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03254186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Propranolol Hydrochloride
Trials testing the same drug.
- NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
- NCT06445166 — Propranolol for the Treatment of Kaposi Sarcoma in Adults · Phase 2 · recruiting
- NCT05997732 — Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences · Phase 4 · recruiting
- NCT05219799 — Sex Disparities in Hypoxic Vasodilation and Impact of Obesity · EARLY_PHASE1 · recruiting
- NCT05651594 — Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanc · Phase 2 · recruiting
Other recruiting trials for Tardive Dyskinesia
Currently open trials in the same condition.
- NCT07173920 — Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localizat · NA · recruiting
- NCT03495024 — Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates · Phase 4 · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03254186 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 26 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03254186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing